The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes by Tamara K. Moyo, Jason H. Mendler, Raphael Itzykson, Ashwin Kishtagari, Eric Solary, Adam C. Seegmiller, Aaron T. Gerds, Gregory D. Ayers, Amy E. Dezern, Aziz Nazha, Peter Valent, Arjan A. van de Loosdrecht, Francesco Onida, Lisa Pleyer, Blanca Xicoy Cirici, Raoul Tibes, Klaus Geissler, Rami S. Komrokji, Jing Zhang, Ulrich Germing, David P. Steensma, Daniel H. Wiseman, Michael Pfeilstöecker, Chiara Elena, Nicholas C. P. Cross, Jean-Jacques Kiladjian, Michael Luebbert, Ruben A. Mesa, Guillermo Montalban-Bravo, Guillermo F. Sanz, Uwe Platzbecker, Mrinal M. Patnaik, Eric Padron, Valeria Santini, Pierre Fenaux, Michael R. Savona, On Behalf of the MDS/MPN International Working Group

Get full text